NEJM editor-in-chief class: The editor-in-chief criticizes commercial interests for obstructing clinical research on new trends in tumor immunotherapy (part 2)

On the occasion of ASCO 2021, the annual event of clinical oncology, NEJM Medical Frontier invited Dr.
Dan Longo, the editor in charge of the New England Journal of Medicine (NEJM), to summarize the progress of tumor immunotherapy in the past three years and clarify the main lines and trends of frontier progress.

In the second part of today’s broadcast, Dr.
Longo bluntly stated that “most pharmaceutical companies are not willing to conduct joint drug research on drugs owned by them and other companies’ drugs”, and true scientific progress requires us not to care about which pharmaceutical company, but to use Wisdom, and put forward new ideas based on the results of pilot tests.
"
The speaker introduced that Dr.
Longo is currently the Deputy Editor of NEJM, responsible for reviews and manuscripts in the field of oncology.

Professor of Harvard Medical School and concurrently a senior physician at Brigham and Women's Hospital.

Member of the American Association for the Advancement of Science (AAAS).

He is also the editor of Harrison's Principles of Internal Medicine.

He has published more than 980 papers and monograph chapters, and is the author of the top 1% global citation rate in the field of life sciences.

Dr.
Longo's scientific research interests focus on the mechanisms of tumor suppression of T cells and other fields.
He has developed multiple therapies that have improved the survival of patients with tumors such as lymphoma.

What elements are required for excellent clinical research in the classroom as the editor-in-chief of NEJM? Can negative results be published in high-impact journals? What types of clinical research does the New England Journal of Medicine favor? What are the characteristics of clinical research in various specialties, and what are the cutting-edge developments? We will successively launch clinical research and paper publishing courses led by the editors of the New England Journal of Medicine (NEJM).

Related reading NEJM Editor-in-Chief Class: New Trends in Tumor Immunotherapy (Part 1) NEJM Editor-in-Chief Class: Excellent Clinical Research from the Perspective of NEJM (Part 1) NEJM Editor-in-Class: Excellent Clinical Research from the Perspective of NEJM (Part 2) Copyright Information This article is from Jiahui Medical Research Translation, writing or commissioning of "NEJM Frontiers in Medicine" jointly created by J-Med and New England Journal of Medicine (NEJM).

The Chinese translation of the full text and the included diagrams are exclusively authorized by the NEJM Group.

If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn.

Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal liabilities.